Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

AnPac Bio-Medical Science said on Thursday that it has priced its initial public offering of roughly 1.3 million American depositary shares (ADS) at $12 apiece, for total proceeds of around $16.0 million.

BGI and its subsidiary MGI Tech said this week that their ultra-high-throughput sequencer DNBSEQ-T7, a metagenomic sequencing kit for coronaviruses, and 2019 novel coronavirus (2019-nCoV) reverse transcription PCR kit have all received emerg

Guided Therapeutics is kicking off 2020 with a renewed focus. The Norcross, GA-based company is renewing a bid for FDA approval of its painless cervical cancer detection test. GT will also raise funds to enhance sales outside of the U.S. for

Abbott Laboratories has won a nod from FDA for a new alternative surgical technique for the HeartMate 3 Left Ventricular Assist Device (LVAD).

Personalized medicine is also advancing thanks to advances in in vitro diagnostics technology

“Additive manufacturing has made its way into our healthcare system,” says Mark Wehde of Mayo Clinic Division of Engineering

Wearable technologies could help address some of our greatest healthcare unmet needs, says Maria Shepherd of Medi-Vantage. While “wearable medical technology is in its infancy,

“2019 was really the year of connected care/digital health—and there’s so much more to come,”

One of the biggest deals in diagnostics this year could be in the process of unfolding, according to a report from Bloomberg. The media outlet is reporting that Thermo Fisher Scientific has approached Qiagen to acquire it in a deal valued at

A common cardiac blood test done before surgery can predict who will experience adverse outcomes after most types of surgery, said researchers from Hamilton Health Sciences.